Investors
|
Regenerative MedicalM technologies have been developing for over 40 years and particularly with the rapid advancement of stem cell biology (including both embryonic and adult stem and progenitor cells), the field is rapidly emerging and moving towards a tipping point of clinical impact. On the one side this "technology push" is now characterized by increased government funding and the proliferation of dedicated RM academic research programs. On the other side a "market pull" is characterized by an increased demand from an aging population with unmet medical needs and from the trend of big pharma re-engaging in this field. In response to these market dynamics, many early stage regenerative medicine companies were formed, which will be able to advance and prevail in a large market poised for rapid growth. As investors, the key is having the skills and knowledge to identify, select and guide these emerging RM companies. Proteus Venture Partners will build value in its portfolio companies, not simply by providing capital, but by actively mentoring its companies through key milestones including: |
Most importantly, Proteus Venture Partners will determine value inflection points on a risk adjusted NPV basis and guide management toward financings and exits at the point of maximum value. Our investment team and Advisory Board represent the thought leaders on the market and technologies of regenerative medicine. Proteus Venture Partners have the background, knowledge and network that will enable them not only generate substantial deal flow, but help them perform deep and rigorous diligence. Our disciplined process helps us evaluate all the key metrics including:
If you would like to contact us regarding investment opportunities, please send us an email at: info@proteusvp.com. |